Abingdon Health plc (AIM: ABDX), the York-headquartered rapid diagnostics developer and contract manufacturer, has signed a Memorandum of Understanding with Centre for Process Innovation (CPI) to explore collaboration across the MedTech sector. The agreement, announced on 16 November 2026, is designed to create a structured route for diagnostics innovators to move from early-stage technology development through to regulatory approval, scale-up manufacturing and commercial deployment. The partnership combines CPI's expertise in MedTech technology development with Abingdon Health's established contract development, regulatory and commercialisation capabilities, and builds on the company's recent expansion into the United States.

Key Points

  • Abingdon Health plc (AIM: ABDX | OTCQB: ABDXF) — York-headquartered rapid diagnostics CDMO and regulatory services provider
  • MoU signed with Centre for Process Innovation to collaborate on MedTech development, scale-up and commercialisation
  • Both organisations hold ISO 13485-certified quality systems, expected to simplify technology transfer between the two parties
  • Investors may watch for specific programmes transitioning under the MoU and any commercial contracts arising from the collaboration

How the Abingdon Health and CPI Partnership Structures the MedTech Innovation Pipeline

Under the MoU, CPI will support innovators during early-phase technology development, proof of concept, prototyping and process development. Programmes will then be transitioned to Abingdon Health for product verification, validation, regulatory support and scalable manufacturing. The announcement states that both organisations hold ISO 13485-certified quality systems, which the companies expect will simplify and accelerate technology transfers between the two parties. The collaboration is intended to address what the announcement describes as one of the sector's most significant challenges: bridging the gap between breakthrough innovation and successful commercial adoption.

Broad MedTech Application Scope Covering Diagnostics, Biosensors and Wearable Technologies

The organisations expect the collaboration to generate opportunities across in vitro diagnostics, biosensors, wearable technologies, digital health solutions and next-generation medical devices. CPI brings expertise in developing complex MedTech technologies including connected health devices and advanced medical products, while Abingdon Health contributes contract development and manufacturing, performance evaluation, clinical trial management and commercialisation support. The announcement suggests the combined offering is intended to help innovators reduce risk, shorten development timelines and improve their path to market readiness, though no specific programmes, revenue projections or contract values were disclosed.

US Expansion Context Underpins Abingdon Health's Strategic Rationale for CPI Collaboration

The announcement explicitly links the MoU to Abingdon Health's recent expansion into the United States, noting the partnership will further the organisation's ability to respond to growing demand for innovative development and manufacture of rapidly deployable diagnostic testing solutions. Abingdon Health operates laboratories and commercial offices in Madison, Wisconsin, alongside its UK facilities in York and Doncaster. The company was founded in 2008 and operates as a CDMO, offering lateral flow product development, regulatory strategy and technology transfer services to an international customer base across the UK, EU and USA.

MoU Status Means Commercial Outcomes Remain Subject to Further Negotiation

It is important to note that a Memorandum of Understanding represents a framework for exploring collaboration rather than a binding commercial contract. The announcement confirms the two parties will work together to identify suitable opportunities, but no specific programmes, financial terms or revenue commitments were disclosed. Abingdon Health's ability to convert this strategic relationship into contracted revenue will depend on the pipeline of MedTech innovators seeking combined development and commercialisation support — a dynamic that investors may choose to monitor as the partnership progresses.